Exercising current treatments for erectile dysfunction in diabetes: effective, economic and ego-boosting
نویسندگان
چکیده
منابع مشابه
Vardenafil – A new and effective treatment for erectile dysfunction
Vardenafil (Levitra, Bayer Healthcare/GlaxoSmithKline, USA) is a phosphodiesterase 5 inhibitor developed specifically for use as an oral therapy for erectile dysfunction (ED). This review provides an overview of recent clinical trial results that support the use of this compound as first-line therapy in patients with ED. Specifically, data from clinical trials performed in multiple countries ha...
متن کاملCurrent concepts in the evaluation and management of erectile dysfunction.
The field of erectile dysfunction continues to evolve. Updated AUA Erectile Dysfunction Guidelines and the second Princeton Consensus Panel Guidelines, as well as updates regarding the oral PDE-5 inhibitors, are the focus of this article.
متن کاملAB028. Current status of pharmacotherapy for erectile dysfunction
The men’s desire to have larger and longer penis have created endless medical demands throughout human history. Until up to date, various medical skills for penile augmentation have developed in aspect of experimental and clinical outcome. Recently with throwing away socially unacceptable ideas, the need for penile augmentation is considered as equivalent level with mammoplasty for breast augme...
متن کاملFertility Treatments as a Cause of Erectile Dysfunction
The setting of fertility treatments may pose an immense amount of stress on the couple involved. During fertility treatments the male partner is required to perform at specific times, whether as part of sexual intercourse or as part of supplying a semen specimen. The correlation between stress and erectile dysfunction (ED) has been evaluated and shown in past studies, but in the setting of assi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Practical Diabetes International
سال: 2004
ISSN: 1357-8170,1528-252X
DOI: 10.1002/pdi.650